DAMORA THERAPEUTICS INC (DMRA)
NASDAQHealth CareBiotechnologySnapshot 2026-07-07
$30.00+0.67%
Close 2026-07-07 · 1-day change
Reading DMRA? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track DMRA free→NASDAQHealth CareBiotechnologySnapshot 2026-07-07
Reading DMRA? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track DMRA free→QuarterlyIQ Insights · DMRA
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated weak grew net income 30% of the time over the next year (vs 50% for the rest of the cohort, n=9274).
Over the trailing year it converted 0.11x of net income into operating cash flow.
Not enough signal yet.
Not enough signal to read sensitivity to the US dollar, the broad stock market, real (inflation-adjusted) rates, Fed net liquidity, long-term interest rates (low R² over the window).
18 material management or governance events in the past 24 months, led by executive changes. Historically, Health Care names rated volatile grew net income 49% of the time over the next year (vs 48% for the rest of the cohort, n=3770).
Not investment advice. As of 2026-07-07.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.